Short Interest in Aclarion, Inc. (NASDAQ:ACON) Increases By 535.7%

Aclarion, Inc. (NASDAQ:ACON) was the target of a large growth in short interest in October. As of October 15th, there was short interest totaling 80,100 shares, a growth of 535.7% from the September 30th total of 12,600 shares. Approximately 13.9% of the company’s stock are short sold. Based on an average trading volume of 134,200 shares, the days-to-cover ratio is currently 0.6 days. Based on an average trading volume of 134,200 shares, the days-to-cover ratio is currently 0.6 days. Approximately 13.9% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aclarion in a research report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus target price of $11,758.50.

Aclarion Stock Performance

NASDAQ ACON opened at $7.88 on Thursday. The stock has a 50-day simple moving average of $7.79 and a two-hundred day simple moving average of $7.47. The firm has a market capitalization of $4.57 million, a P/E ratio of -0.01 and a beta of 1.40. Aclarion has a fifty-two week low of $6.20 and a fifty-two week high of $3,499.51.

Aclarion (NASDAQ:ACON) last released its quarterly earnings data on Thursday, August 14th. The company reported ($2.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by ($0.49). The company had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. Aclarion had a negative net margin of 11,238.59% and a negative return on equity of 83.63%. As a group, analysts forecast that Aclarion will post -263.33 earnings per share for the current year.

Aclarion Company Profile

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.